You are here

Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Aichi Children`s Health and Medical Center
Obu-shi, Aichi, 474-8710 Japan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Status Epilepticus
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
3 + months
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects with status epilepticus or repetitive status epilepticus / cluster seizure
who have seizures that can be evaluated by investigator's visual observations based on
motor symptoms or who have seizures that can be evaluated by EEG.

- Subjects with status epilepticus accompanied by generalized seizure, partial seizure
or secondarily generalized seizure lasting 5 minutes or longer

- Subjects with repetitive status epilepticus / cluster seizure accompanied by not less
than 3 consecutive episodes of generalized seizure, partial seizure or secondarily
generalized seizure in 1 hour.

- Subjects not younger than 3 months (either gender is eligible for the study)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects with known or suspected recurrent seizures due to illegal drug or alcohol
withdrawal

- Subjects with known history of hypersensitivity to lorazepam or benzodiazepine

- Subjects with a known history of benzodiazepine abuse.

- Subjects currently receiving lorazepam

- Subjects with angle-closure glaucoma

- Subjects with myasthenia gravis

- Subjects with either of aspartate transaminase, alanine transaminase, total bilirubin,
blood urea nitrogen, or creatinine at screening visit exceeding 2x the upper limit of
normal of the institutional reference value (if the data is available)

- Subjects with white blood cell count less than 3000/mm3 or neutrophil count less than
1500/mm3 at screening visit (if the data is available)

NCT02239380
Pfizer
Completed
Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Status Epilepticus
NCT03905798
All Genders
0+
Years
Tokyo, Shibuya-ku

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now